Department of Surgery, University of Toronto, Toronto, ON, Canada.
Lallemand BioIngredients, Montreal, QC, Canada.
Exp Brain Res. 2023 Jul;241(7):1931-1943. doi: 10.1007/s00221-023-06651-4. Epub 2023 Jun 26.
Ischemic stroke is a debilitating neurological disease with few effective therapeutics. Previous work has shown that oral probiotic treatment prior to stroke can attenuate cerebral infarction and neuroinflammation, highlighting the gut-microbiota-brain axis as a novel therapeutic target. Whether a more clinically relevant, post-stroke, administration of probiotics can improve stroke outcomes is unknown. In this study, we examined the effect of post-stroke oral probiotic therapy on motor behavior in the pre-clinical mouse endothelin-1 (ET-1) model of sensorimotor stroke. We found that post-stroke oral probiotic therapy with Cerebiome (Lallemand, Montreal, Canada), containing B. longum R0175 and L. helveticus R0052, improved functional recovery and changed the composition of the post-stroke gut microbiota. Interestingly, oral Cerebiome administration did not result in alterations of lesion volume or the number of CD8+/Iba1+ cells in the injured tissue. Overall, these findings suggest that probiotic treatment following injury can improve sensorimotor function.
缺血性脑卒中是一种致残性的神经系统疾病，目前有效的治疗方法很少。先前的研究表明，脑卒中前口服益生菌治疗可以减轻脑梗死和神经炎症，这凸显了肠道微生物群-脑轴作为一种新的治疗靶点。脑卒中后给予益生菌治疗是否能改善脑卒中的预后尚不清楚。在这项研究中，我们研究了脑卒中后口服益生菌治疗对感觉运动性脑卒中的内皮素-1（ET-1）模型小鼠运动行为的影响。我们发现，脑卒中后用 Lallemand（加拿大蒙特利尔）的 Cerebiome（含有 B. longum R0175 和 L. helveticus R0052）进行口服益生菌治疗可改善功能恢复，并改变脑卒中后肠道微生物群的组成。有趣的是，口服 Cerebiome 治疗并没有改变损伤组织中的病变体积或 CD8+/Iba1+细胞的数量。总的来说，这些发现表明，损伤后进行益生菌治疗可以改善感觉运动功能。
